Sh­iono­gi backs F2G in de­vel­op­ing rare-dis­ease an­ti­fun­gal in Eu­rope and Asia

Sh­iono­gi, an ac­tive play­er in the arid field of an­timi­cro­bials, has now set its eye on the ad­ja­cent sphere of an­ti­fun­gals.

The Japan-based phar­ma is part­ner­ing with F2G, which de­scribes it­self as a “rare fun­gal dis­ease com­pa­ny,” to push F2G’s olo­rofim through clin­i­cal tri­als and reg­u­la­to­ry ac­tion in Eu­rope and Asia, the two com­pa­nies an­nounced to­day. Olo­rofim is be­ing test­ed to treat in­va­sive as­pergillo­sis, a rare mold in­fec­tion that can im­pact im­muno­sup­pressed peo­ple, specif­i­cal­ly those that have re­ceived cer­tain can­cer ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER